cyrilzakka/clinical-trials huggingface dataset:
GLP-1 Loading During Elective Percutaneous Coronary Intervention

Angina is caused by narrowings or blockages within coronary arteries. Coronary angioplasty and stenting is performed for people with angina to improve the blood supply to the heart by placing metal tubes within the artery using balloon inflation. The procedure risks small but significant damage to the heart muscle downstream of the balloon.

Glucagon like peptide 1 (GLP 1) is a naturally occurring hormone secreted by cells in the gut in response to food. It acts by stimulating the release of insulin. In the heart it acts to increase glucose uptake into cardiac muscle. GLP-1 can protect the heart and improve heart muscle performance in people with coronary artery disease in physiological studies. This study which assesses whether GLP-1 protects the heart during coronary angioplasty and stenting.

The hypothesis is that GLP-1 given during elective coronary angioplasty and stenting will reduce cardiac troponin rise (a measure of heart muscle damage) compared to placebo.


Eligibility Criteria:
Inclusion criteria:

* Undergoing elective PCI
* Age over 18
* Able to give informed consent

Exclusion criteria:

* Severe co-morbidity (expected life expectancy \< 6 months)
* Nicorandil, glibenclamide, sitagliptin, vildagliptin, saxagliptin, linagliptin, liraglutide, exenatide and insulin use
* Women of child bearing age
* Breast-feeding women
* Myocardial infarction within the previous 3 months
* Baseline elevation of Troponin I before PCI
* Chronic Renal Impairment (serum creatinine \> 160 μmol/l)
Menstrual Blood Stem Cells in Poor Ovarian Responders

In this controlled trial, poor ovarian responder women will be treated with transplantation of autologous menstrual blood stem cells. The investigators will attempt to assess the safety and efficacy of this procedure for the treatment of infertility in POR patients compared to control group.

With economic development, procreation delays have resulted in more women seeking medical help for infertility treatment. Because the quality and quantity of oocytes are affected by physiological age, despite advances in assisted reproductive technology (ART), managing infertility in women with poor ovarian response (POR) remains a daily challenge for physicians.

Adult mesenchymal stromal cell (MSC) therapy has gained particular interest in recent years because it may provide a supportive microenvironment for oocyte development from quiescent primordial follicles. Human MSC transplantation has been shown in preclinical studies to host ovaries and restore their function and structure premature ovarian failure (POF) animal models.

Because of their encouraging characteristics such as ease of access, high availability, monthly repeatability of sampling, less ethical considerations, lack of tumor-causing potential, protected property, and significant trans-differentiation capacity, endometrial-derived stromal cells have been considered in a wide range of studies since 2007. Menstrual blood-derived stromal cells (MenSCs), on the other hand, are derived from endometrial tissue and can be collected in a non-invasive manner, making them especially useful in the treatment of reproductive disorders. The investigators attempted to assess the safety and efficacy of intraovarian injection of MenSCs for the treatment of infertility in POR patients based on this evidence.

The results of this clinical trial's phases I and II indicated that Men-MSCs could be considered as a potential treatment to restore the fertility capability of POR women. Based on these findings, the investigators have designed a Phase III controlled trial of autologous MenSC therapy for patients with POR.

Eligibility Criteria:
Inclusion Criteria:

* Serum AMH \< 0.1 ng/ml (at the screening visit and in the absence of OC or sex-steroid intake)
* Antral follicular count (AFC) in both ovaries \< 4 (at screening visit and in the absence of OC or sex-steroid intake)
* Positive history of at least1 standard previous IVF-ET or ICSI-ET
* Normal thyroid hormones (TSH and FT4)
* Normal level of prolactin,
* Normal level of fasting blood sugar
* Normal Liver tests (SGOT, SGPT)
* Normal level of BUN, creatinine
* Negative Infectious tests (HIV, HCV, HBS Ag, VDRL)
* Normal coagulation factors (PT, PTT, BT, CT)
* Normal serum levels of sodium, potassium, calcium, phosphorus
* Negative history of endometrioma or other ovarian cysts
* Negative history of previous ovarian surgery
* Negative history of cancer
* Negative history of a known autoimmune disorder.

Exclusion Criteria:

* Positive history of hydrosalpinx or anatomical uterine disorders (In vaginal sonography or HSG)
* Severe male factors of their husbands (count \<15 million/ml)
Efficacy and Safety Study of Neuramis in Correction of Nasolabial Fold

This study design is a randomized, multi-center, double Masked, matched Pairs, active-controlled clinical trial. Subjects who voluntarily signed the informed consent and are judged to be eligible for this study will be intradermally injected both of study device and comparator device. Subjects will be randomized to receive injection of study device and comparator device on their each nasolabial fold. Efficacy is evaluated based on the change in Wrinkle Severity Rating Scale (WSRS) from baseline. Safety will be assessed based on 24 weeks follow up visits and subject diary which will be given to subjects during the first 2 weeks after the injection. Any uncomfortable things and adverse events will be investigated from subeject diary and follow up visits.


Eligibility Criteria:
Inclusion Criteria:

1. Men and women aged between 30 and 75
2. Subjects who wanting to correct his/her nasolabial fold and attaining grade 3 or 4 in the Wrinkle Severity Rating Scale(WSRS) of nasolabial fold
3. Subjects whose nasolabial folds are visually symmetric
4. Subjects who agreed to restrict any treatment for the wrinkle correction at the lower orbital rim area for the duration of the study
5. Subjects who can understand and comply with the instructions and all visit schedule
6. Subjects who voluntarily decided the participation of the study and signed the informed consent

Exclusion Criteria:

1. Subjects who had anti-coagulant therapy(excluding low-dose aspirin therapy(100mg, maximum 300mg/day dose)) within 2 weeks from the screening date
2. Subjects who had previous treatment at the lower orbital rim for wrinkle correction(e.g., face lift, soft tissue augmentation, medium depth peels, dermal photorejuvenation) within 6 months from screening date
3. Subjects who were treated calcium hydroxyapatite at the NLF area within a year from screening date
4. Subjects who had dermal augmentation permanent implants(e.g., silicone, Softform®) at the NLF area
5. Subjects who have a scar or skin lesion which can be affect to efficacy to the NLF area
6. Subjects who had anaphylaxis or severe combined allergy or allergy to lidocain or hyaluronic acid
7. Subjects who had a history of keloid formation or hypertrophic scar
8. Subjects who have a skin disorder or wound infection in the NLF area
9. Subjects who participated in other clinical trial within 30 days from screening date
10. The childbearing subjects who disagreed with medically acceptable contraception(e.g., condom, oral contraceptives continuing at least 3 months, contraceptives for injection or insertion, intrauterine contraceptive devices)
11. Pregnant or lactating subjects
12. Patients who are not eligible for this study at the medical discretion of the investigator
Coronary CT Angiography in Non ST-elevation Myocardial Infarction

Non ST-elevation myocardial infarction (NSTEMI) represents 70-75% of all myocardial infarctions. Current guidelines recommend invasive angiography and this patient group represents a major burden on the invasive catheterization laboratories and the health care system.

The coronary pathology found in NSTEMI-patients varies substantially, ranging from structurally normal vessels, non-obstructive atherosclerosis to severe multivessel disease. 30-40 % of patients with NSTEMI undergoing invasive coronary angiography do not undergo revascularization. If these patients could be identified by a non-invasive method like coronary CT angiography (CCTA), an invasive procedure with the potential risk for complications could be avoided. Furthermore, less patients would need transfer to an invasive center. Both for patients and for health care costs this would be of major benefit.

The quality of CCTA images has improved during the years, and radiation dose has decreased. Due to technological development it is now possible to perform high quality coronary CCTA with a very low radiation dose (1-1.5 mSv) compared to a radiation dose of 3-4 mSv for invasive coronary angiography.

The overall aim of the project is to define a subpopulation of NSTEMI patients that preferably should undergo CCTA as the first step in imaging of the coronary arteries and thus potentially be saved from an unnecessary invasive investigation. This would result in less patient discomfort, less patient risk and reduced health care costs. Patients with a clinical indication for invasive angiography according to current guidelines will undergo CCTA prior to the invasive investigation. The ability of CCTA to identify those with no need for revascularization will be assessed using invasive angiography as the gold standard.


Eligibility Criteria:
Inclusion Criteria:

* admitted to a local hospital with NSTEMI type 1 or type 2 based on clinical criteria
* indication for invasive coronary angiography according to current guidelines

Exclusion Criteria:

* indication for immediate (\< 2 hours) invasive strategy according to guidelines
* GRACE score \> 140
* not willing to provide written informed consent
* previous coronary revascularization
* estimated glomerular filtration rate \< 30 mL/min/1,73m2
* allergic reactions to contrast agents impeding for safe examinations
* \> 2 hypokinetic segments on echocardiography
Clinical Study to Assess High-DHA Fish Oil on Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy

The objective of this study is to determine the acute and chronic \[4-week\] effects of a high-DHA fish oil supplement on fasting and post-prandial (post-meal) biomarkers of cardiovascular disease risk, in adults on Statin therapy.

This study involves fasted and post-prandial components.

Fasted Study:

Participants will provide fasting blood samples pre-and post-intervention \[4-week administration of supplement or placebo\] in Treatment Period I. Participants will again provide fasting blood samples pre-and post-intervention \[4-week administration of supplement or placebo, opposite to Treatment Period I\] during Treatment Period II.

There will be a 4-week washout period during the two Treatment Periods.

Post-prandial study:

Participants will also complete a post-prandial study pre-and post-intervention during each Treatment Period.

Eligibility Criteria:
Inclusion Criteria:

* Be an adult between the ages of 18 and 70;
* Be a male or a post-menopausal female who has gone a minimum of one year since their last menses;
* Be taking Statin medication at a stable dose for a minimum of four weeks prior to study commencement \[and whom have reached a target LDL level\];
* Have elevated fasting triglyceride levels \[greater than 1.5 mmol/L but less than 5.7 mmol/L\];
* Have fasting blood glucose levels below the study cut-off \[less than 7.0 mmol/L\];
* Have a Body Mass Index (BMI) less than 35.0
* Be taking natural health products BUT agree to cease consumption during the study period and a 4-week pre-study washout prior to study commencement. Study participants will be allowed to consume a daily multivitamin if they have been doing so at a stable dose for a minimum of three months prior to study commencement.

Exclusion Criteria:

* Be younger than 18 years of age or older than 70 years of age;
* Be an adult pre- or peri-menopausal female;
* Not have taken Statin medication at a stable dose for a minimum of 4 weeks prior to study commencement;
* Have fasting triglyceride levels outside of study limits\[ie/ less than 1.5 mmol/L or greater than 5.7 mmol/L\];
* Have elevated fasting blood glucose levels \[greater or equal to 7.0 mmol/L\];
* Have high blood pressure \[greater than 140/100\]
* Have a Body Mass Index (BMI) equal to or greater than 35.0
* Have a pre-existing cardiovascular disease or illness, including angina, myocardial infarction, stroke, intermittent claudication or transient ischemic attack;
* Have a known allergy to fish and/or fish oil, olive oil, soy or Vitamin E;
* Be taking natural health products but are unwilling to cease consumption during the study period and a 4-week pre-study washout prior to study commencement;
* Consume more than two (2) fish meals on a weekly basis
* Consume excessive amounts of alcohol on a weekly basis \[more than 10 alcoholic drinks per week\];
* Anticipate or have planned surgery during the course of the study.
Women's Estrogen for Stroke Trial (WEST)

To determine if estrogen hormone replacement therapy reduces the risk of stroke or death in postmenopausal women who have already had stroke or a transient ischemic attack (TIA).

The researchers enrolled 664 postmenopausal women with an average age of 71 years who had experienced an ischemic stroke or a TIA within the previous 90 days. Ischemic strokes and TIAs result from blockages in the vessels that supply blood to the brain. Participants were given a number of initial assessments, including the NIH Stroke Scale (NIHSS) of neurological impairment and the Barthel index of functional ability in activities of daily living. In addition to the usual best care for patients who have had a stroke, women in the trial received either oral estrogen (estradiol 17-beta at the standard replacement dose of 1 mg daily) or a matching placebo. Patients were studied for an average of 2.8 years. They stopped receiving the estrogen or placebo if they had a stroke.

The researchers found that there was no significant difference in the incidence of stroke or death in the women who were randomly assigned to receive estrogen instead of placebo. However, they found that the incidence of death due to stroke was higher in the estrogen group and that the non-fatal strokes in that group were associated with slightly worse neurological and functional impairments at 1 month after stroke. The risk of stroke within the first 6 months after enrollment in the study was also higher among women in the estrogen group. There were no significant differences between treatment groups in the number of TIAs or non-fatal heart attacks. However, participants receiving estrogen were more likely to experience gynecologic complications, particularly vaginal bleeding.

Eligibility Criteria:
Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD)

The purpose of this study is to assess the efficacy of Escitalopram in the treatment of obsessive compulsive disorder and to determine the optimal treatment dose.

Background and Purpose: Obsessive compulsive disorder affects approximately 3% of the population. Treatment options include the selective serotonin reuptake inhibitors (SSRIs), dual serotonin and norepinephrine reuptake inhibitors, and behavioral therapy. A recent double-blind, placebo-controlled trial demonstrated that citalopram is effective in the treatment of OCD. Escitalopram is a new SSRI that may be more effective than other SSRIs for the treatment of major depression and may have fewer side effects. This study aims to assess the efficacy of escitalopram for the treatment of OCD.

Comparisons: Subject Y-BOCs pre-post treatment. We will also compare the improvement of subjects across the three different medication levels: 10 mg, 20 mg, and 30 mg.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of OCD by DSM-IV
* Age 18-65
* Y-BOCS greater than 20
* Written informed consent
* Females of childbearing potential must have a negative serum or urinary beta-HCG test.

Exclusion Criteria:

* Pregnant women or women of childbearing potential who are not using a medically accepted means of contraception.
* Patients who, in the investigator's judgement, pose a serious suicidal or homicidal risk.
* Serious or unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease. Patients on anticoagulant therapy.
* History of seizure disorder
* Comorbid bipolar disorder, psychosis, organic mental disorder, or developmental disorder
* If there is a history of substance abuse, patients in remission at least 6 months.
* Currently being treated with behavioral therapy, specifically exposure and response prevention, for OCD.
* Other medications for medical disorders that may interfere with escitalopram
* Current major depression or prescribed an antidepressant for major depression within the past 12 months.
* Taken an SSRI medication within 2 weeks of beginning the study (4 weeks for fluoxetine).
* More than 1 adequate trial (at least 10 weeks at maximally tolerated dose) with another SSRI in the past.
Effects of Vojta Therapy on the Motor Function of Children With Neuromotor Disorders

Functionality and motor skills during activities of daily living have progressively gained importance as tools for classification, assessment and research of neuromotor disorders and the treatment methodology according to Dr. Vojta or Reflex Locomotion follows this criterion in the clinical field. Vojta therapy is a commonly extended tool in the field of pediatric rehabilitation. This methodology acts on the ontogenic postural function and automatic postural control, on which different environmental aspects will later act. It is not a functional training, to avoid the voluntary movement available according to the pathology by means of compensations. Vojta therapy would be the key to unlock the development of gross motor function, later used in the movement of daily life activities, including other therapies such as conventional physiotherapy, sensory stimulation, occupational therapy, etc. This study aims to demonstrate that there are changes in the motor development of children with cerebral palsy with the application of Vojta Therapy.


Eligibility Criteria:
Inclusion Criteria:

* Male and female children
* Diagnosis of cerebral palsy or neuromotor disease

Exclusion Criteria:

* healthy subjects
* Patients receiving other therapy during the procedure
Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects.

Hyperkalemia is a common life-threatening electrolyte disturbance which may impair cardiac and many other organs' functions. Unfortunately, a well-established guideline for the treatment of hyperkalemia in the emergency setting is still missing. However, the last "Kidney Disease: Improving Global Outcomes (KDIGO)" conference proposed a treatment protocol for hyperkalemia and addressed controversies in this matter. Beta2-agonists were one of the main lines in the approach towards managing a patient with hyperkalemia. However, this evidence was only available for racemic albuterol.

Levalbuterol is the isolated R-enantiomer of racemic albuterol which is comprised of S- and R-enantiomers. Several lab and clinical studies have assessed the effect, affinity, and selectivity of each of the enantiomers. Few studies in medical literature have compared the difference between these two drugs regarding cardiac effects with inconclusive results, and even fewer studies have compared the efficacies of these two drugs regarding potassium lowering effect.

To the investigators' knowledge, no study to date has compared the efficacy and safety of albuterol compared to levalbuterol in hyperkalemic patients with the properly adjusted dosing. So, in clinical practice, the investigators wanted to know based on evidence if levalbuterol can be an effective substitute for albuterol in lowering potassium levels in hyperkalemia patients while yielding fewer cardiac side effects. To answer this question, the investigators designed a single-centered controlled clinical trial that includes adult hyperkalemia patients in Aleppo University Hospital.


Eligibility Criteria:
Inclusion Criteria:

* adult patients
* serum potassium level \>5.9 mEq/L

Exclusion Criteria:

* Pseudohyperkalemia:

  * Hemolysis of blood sample
  * Thrombocytosis \> 10\*6 /mm3
  * Hyperleukocytosis \> 10\*5/mm3
  * Mechanical Trauma during Venipuncture
  * Fist clenching during blood drawing
  * Tourniquet time \> 1 minute
* Diabetes acute complications

  * DKA
  * Hyperosmolar Hyperglycemic Syndrome
* Insulin-dependent diabetes mellitus ( if insulin is taken recently)
* Pregnant women
* Hyperthyroidism
* Hemodynamic instability
* Pacemakers if providing impulses (demand pacemakers that are not firing right now are included)
* Atrial fibrillation or any other arrhythmia
* Baseline tachycardia \>120 bpm
* Acute exacerbations of HF
* Patients expected to require emergency intubation and ventilation
* Patients expected to require dialysis within the first 60 minutes
* Patients with hypersensitivity to the medication
* Patients with Acute Coronary Syndrome
* Patients on beta-blockers / beta-agonists or anti-arrhythmic drugs
* Patients with severe dyspnea or hypoxia SpO2 \<90%
Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%

The purpose of this study is to determine whether Adapalene, 0.1% is safe and effective in the treatment of Acne Vulgaris.

This study will compare the efficacy and safety of Adapalene, 0.1% and vehicle in the treatment of subjects with Acne Vulgaris. This is a multi-center, randomized, double-blind, parallel, vehicle controlled study involving subjects with acne vulgaris meeting pre-specified inclusion/exclusion criteria. Male and female subjects, 12 years of age or older, with 20-50 papules and pustules and 30 to 100 non-inflammatory lesions and have an Investigator's Global Assessment (IGA) score of 3 (Moderate) or 4 (Severe) are eligible for enrollment. One nodule may be present at inclusion. Acne lesions are evaluated on the face only. Subjects presenting with facial and truncal acne vulgaris can participate in this study. Subjects will be randomized in a 1:1 ratio to Adapalene, 0.1% or Vehicle.

Eligibility Criteria:
Inclusion Criteria:

* Subjects with Moderate or Severe Acne Vulgaris,
* 20-50 papules and pustules in total on the face excluding the nose
* 30-100 non-inflammatory lesions on the face excluding the nose.
* Negative urine pregnancy test for all females.

Exclusion Criteria:

* Subjects with more than one acne nodule.
* Subjects with any acne cyst on the face.
* Subjects with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), or severe acne requiring systemic treatment.
* Subjects with underlying diseases or other dermatologic conditions that require the use of interfering topical or systemic therapy, such as, but not limited to, atopic dermatitis, perioral dermatitis or rosacea.
* Subjects who are pregnant, nursing, or planning a pregnancy.